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1. Introduction 
Initially, CLL was considered as a homogeneous disease caused by the accumulation of 
functionally incompetent B lymphocytes carrying no mutations in the immunoglobulin heavy 
chain variable (IgVH) genes. However, further studies by Schroeder and Dighiero suggested 
that IgVH genes may be mutated in CLL (Schroeder & Dighiero 1994). This report changed the 
general view of CLL and gained even more significance when the mutational status of the IgVH 
genes was linked to the prognosis of the patients in two independent studies (Damle et al. 1999, 
Hamblin et al. 1999). These studies showed for the first time that patients with CLL cells 
expressing unmutated IgVH genes presented with a more aggressive disease and shorter 
survival than those with cells carrying mutated IgVH genes. Determination of the mutational 
status of the IgVH genes in CLL patients became of great interest, but even today remains 
difficult to carry out in most medical centers since the technique is laborious, expensive and 
time-consuming. Therefore many efforts have been made to identify possible surrogate markers 
with the same prognostic value as the mutation status. In 2001, two independent groups 
published their studies in which they compared the gene expression profiles for IgVH mutated 
versus unmutated CLL cells. Because, the description of the two groups of CLL with markedly 
different prognosis prompted the idea that CLL consisted of two different entities originating 
from either naive or memory cells, it was unexpected that only a few differentially expressed 
genes were found (Rosenwald et al. 2001, Klein et al. 2001). Among them, ZAP-70 appeared to 
be one of the most significant (Rosenwald et al. 2001). Subsequently, the correlation of ZAP-70 
expression with the mutational status of the IgVH genes was assessed in larger series of CLL 
patients, where ZAP-70 was mostly found expressed in unmutated CLL (reviewed in (Van 
Bockstaele et al. 2009)). Further clinical studies revealed that ZAP-70 was also an independent 
prognostic marker (Bosch et al. 2006). There were several attempts to standardize the 
determination of ZAP-70 expression by flow cytometry (Crespo et al. 2003, Wang et al. 2011, 
Van Bockstaele et al. 2006). Although, a successful standardized procedure was put forward by 
the European Research Initiative on CLL (ERIC), the determination and interpretation of ZAP-
70 remains difficult (Letestu et al. 2006) and optimalization is still ongoing. 
2. Structure of ZAP-70 
The zeta-chain associated protein kinase with a molecular weight of 70 kDa, ZAP-70, is a 
member of the Syk family kinases predominantly involved in T cell receptor (TCR) signaling 
initiation and subsequent T cell activation (Chan et al. 1992). The ZAP-70 gene is located on 
www.intechopen.com
 Chronic Lymphocytic Leukemia 
 
136 
chromosome 2q11.2 and is composed of 14 exons encoding a protein tyrosine kinase (PTK) 
made out of 619 amino acids building three functional domains; two Src homology 2 (SH2) 
domains arranged in tandem at the amino-terminus and a tyrosine kinase domain at the 
carboxy-terminus (Figure 1) (Au-Yeung et al. 2009). 
 
ID-A: interdomain A; ID-B: interdomain B; Y: Tyrosine residue 
Fig. 1. Zeta-chain-associated protein kinase 70 (ZAP-70) protein structure. 
The two SH2 domains are separated by a linker region known as interdomain A (ID-A) and 
a linker region known as interdomain B (ID-B) connecting the SH2 domains to the kinase 
domain. SH2 domains are involved in the recruitment of ZAP-70 to phosphorylated 
immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 ζ chain homodimers 
and both SH2 domains are responsible for ZAP-70 dependent signal transduction. The 
kinase domain of ZAP-70 contains two tyrosine residues, Tyr492 and Tyr493, which are 
phosphorylated by the Src tyrosine kinase, Lck, or autophosphorylated by ZAP-70 itself, 
after TCR engagement. Mutation of Tyr493 impairs ZAP-70 kinase activity, revealing a 
positive regulatory role of this residue, while mutation of Tyr492 increases kinase activity, 
indicating its inhibitory role (Wange et al. 1995). The tyrosine 474 of ZAP-70 is required for 
association with the Src Homology 2 domain Containing (Shc) adaptor protein and coupling 
of the activated TCR to the Ras/Raf/Erk pathways. Although the catalytic activity of ZAP-
70 represents its major function, it is likely that interactions of ZAP-70 with other proteins 
contribute to its role in signal transduction. Interdomain B contains three tyrosines, Tyr292, 
Tyr315 and Tyr319, also representing important phosphorylation targets (Au-Yeung et al. 
2009). These three tyrosines are phosphorylated by one of the Src family kinases, i.e. Lck or 
Fyn after TCR stimulation in T cells. Each of these binding sites, once phosphorylated, may 
bind to a different signaling molecule, conferring a role of ZAP-70 in the recruitment of 
additional signaling molecules to the antigen receptor complex. Tyr292 is able to bind the E3 
ligase c-Cbl, which might be important for the turnover of the signaling complex (Rao et al. 
2002). This implies a negative regulatory role for this tyrosine that however was recently 
shown to function also as a binding site for the p85 regulatory subunit of PI3K, indicating 
that it may also play a positive role in signal transduction. The two other tyrosines, Tyr315 
and Tyr319 are positive regulators of ZAP-70 activity. Their phosphorylation is important 
for ZAP-70 activity, because it appears to prevent ZAP-70 from returning to an auto-
inhibited conformation (Au-Yeung et al. 2009). Phosphorylated Tyr315 is a binding site for 
the SH2 domain of Vav-1. This plays a key role in activation of the Rho family of GTPases 
involved in cytoskeleton remodeling after receptor stimulation (Wu et al. 1997, Sanchez-
Aguilera et al. 2010). Tyr319 is a binding site for the C terminal SH2 domain of 
phospholipase C Ǆ (PLCǄ), and phosphorylation of Tyr319 is required for PLCǄ 
phosphorylation and subsequent activation of downstream signals, such as calcium 
mobilization or Il-2 production (Williams et al. 1999).  
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3. Expression of ZAP-70 
3.1 Expression of ZAP-70 in T and B cells 
For a long time ZAP-70 expression was considered to be restricted to T and NK cells, until it 
was found to be expressed as well in leukemic cells of CLL patients. Later studies have 
revealed ZAP-70 expression in a subset of normal tonsillar and splenic B cells (Cutrona et al. 
2006, Nolz et al. 2005) and in bone marrow pro-B cells (Crespo et al. 2006, Guillaume et al. 
2005). Besides the occurrence of ZAP-70 in a subset of CLL patients it was also found in a 
number of other human B cell tumors like some cases of mantle cell lymphoma, splenic 
marginal zone lymphoma, B-ALL and Burkitt lymphoma (Crespo et al. 2006, Guillaume et 
al. 2005, Admirand et al. 2004, Chiaretti et al. 2006, Scielzo et al. 2006, Sup et al. 2004, 
Orchard et al. 2005). A correlation was described between maturation of tumor cells and 
expression of ZAP-70, ZAP-70 being more expressed in the more mature cases with IgM, 
higher CD20 expression and pre-B rather than pro-B phenotype (Chiaretti et al. 2006) . 
3.2 Regulation of ZAP-70 expression in CLL cells 
In 2005, Corcoran et al. showed that there was an association between the methylation status 
of the ZAP-70 gene and expression status of ZAP-70 protein (Corcoran et al. 2005). It is well 
established that abnormal methylation is frequent in malignancy. Hypermethylation of CpG 
islands within gene promoters results in gene silencing, while hypomethylaion may cause 
genomic instability or the upregulation of gene expression (Herman & Baylin 2003). 
Specifically, they found that the majority of cases expressing ZAP-70 protein lacked 
methylation in the intron 1-exon 2 boundery region of the ZAP-70 gene. This region was 
found unmethylated in circulating ZAP-70 expressing T cells, but methylated in ZAP-70 
negative normal B cells. These data give a possible explanation for ZAP-70 overexpression 
in a subset of CLL patients. But the absence of an association between ZAP-70 expression 
and methylation status indicates that other factors must play a role. 
ZAP-70 expression in B cells may also be regulated by the heat shock protein (Hsp)90. 
Hsp90 is a molecular chaperone that catalyses the conformational maturation of a large 
number of signaling proteins in cancer that are collectively described as ‘clients’. In 
advanced tumours, it exists in an activated form complexed with other molecular 
chaperones, whereas in normal tissue it is present in a latent, uncomplexed state (Kamal et 
al. 2003). Using inhibitors, Castro et al. have demonstrated that ZAP-70 is an Hsp90 client 
protein in tumour cells, but not in T cells (Castro et al. 2005).  
4. ZAP-70 in lymphocyte receptor signaling 
4.1 ZAP-70 in T cell signaling 
Ligation of the TCR triggers a cascade of intracellular signals that culminate in cytokine 
gene expression, proliferation, and the execution of T cell effector functions. After 
engagement of the TCR with a peptide bound to a major histocompatibility complex 
molecule, a signaling cascade is activated by the sequential activation of two families of 
PTKs. First of all, members of the Src family, Lck and FynT, initiate this process by 
phosphorylating tyrosine residues at the ITAMs of the CD3 ζ subunits. Once the ITAMs in 
the receptor cytoplasmic tails have been phosphorylated, they can recruit the next player in 
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the signaling cascade, ZAP-70, belonging to the second family of the PTKs, the Syk family. 
ZAP-70 binds to the double phosphorylated ITAMs via its SH2 domains with high affinity. 
Recruitment of ZAP-70 to the ITAMs leads to ZAP-70 itself becoming phosphorylated. The 
subsequent activation of bound ZAP-70 by phosphorylation leads to three important 
signaling pathways. ZAP-70 phosphorylates the adaptor proteins linker for activation of T 
cells (LAT) and SH2-domain-containing leukocyte protein (SLP)-76, which in turn leads to 
the activation of PLCǄ and the Rho-GTPase Ras. PLCǄ cleaves phosphatidylinositol 
biphosphate (PIP2) to yield diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 
increases intracellular Ca2+ concentration, activating the phosphatase calcineurin, and 
subsequently calcineurin activates a transcription factor, nuclear factor of activated T cells 
(NFAT). DAG and the increase in Ca2+ concentration activate protein kinase C (PKC). PKC 
will in turn activate the transcription factor, nuclear factor κappaB (NFκB). Another 
pathway involves the Rho-GTPase Ras, which activates a mitogen-activated protein (MAP) 
kinase cascade. This Ras-induced kinase cascade induces and activates Fos, a component of 
the activator protein (AP)-1 transcription factor. The three transcription factors NFκB, NFAT 
and AP-1 act to induce specific gene transcription, leading to cell proliferation and 
differentiation (Figure 2).  
 
 
 
Schematic presentation of the intracellular signaling pathways initiated by the T cell receptor complex (TCR) 
leading to activation of three important transcription factors.  
Fig. 2. ZAP-70 in T cell signaling 
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In addition to its importance in T cell signaling through the TCR, ZAP-70 has also been 
shown to be required for effective signaling by the chemokine CXCL12 (Ticchioni et al. 
2002). CXCL12 is an important chemoattractant for T cells, driving them from the blood to 
tissue sites where they are likely to encounter antigens. Binding of CXCL12 to its ligand 
CXCR4 results in phosphorylation of ZAP-70, which is required for activation of 
downstream proteins, such as ERK and Vav-1, leading to T cell migration. 
4.2 ZAP-70 in CLL B cell signaling  
4.2.1 Normal B cell signaling 
Signaling in normal B cells occurs after crosslinking of the surface immunoglobulin 
molecules (Igǂ and Igǃ) with an antigen. On clustering of the receptors, the receptor-
associated Src-family protein tyrosine kinases Blk, FynB and Lyn are activated. These 
activated kinases phosphorylate the ITAMs in the receptor complex, which bind and 
activate the cytosolic protein kinase Syk. Subsequently, Syk phosphorylates other targets, 
inlucing the adaptor protein BLNK, which help to recruit Tec kinases that in turn 
phosphorylate and activate the enzyme PLCǄ. Similar to T cell signaling, PLCǄ together 
with Ras, leads to activation of the three main signaling pathways to the nucleus: 
activation of NFκB, NFAT and AP-1, initiating new gene transcription that results in the 
differentiation, proliferation and effector actions of B cells (Figure 3).  
 
Schematic presentation of the intracellular signaling pathways initiated by cross-linking of B cell receptors (BCR) 
by an antigen, leading to activation of three important transcription factors. 
Fig. 3. B cell signaling 
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4.2.2 Interplay between ZAP-70, Syk and CLL B cells 
The role of ZAP-70 in proximal signaling after TCR activation and its homology with Syk, 
suggest that ZAP-70 may augment signaling through the BCR, thus, providing a biological 
explanation for the more aggressive clinical outcome of the ZAP-70 positive subgroup of 
patients (Chen et al. 2002). Nevertheless, the molecular mechanisms underlying the role of 
ZAP-70 in BCR signaling remain largely unknown. In Figure 4 the interactions between 
ZAP-70, Syk and BCR signaling is shown.  
Studies, performed in the eighties and nineties had indicated that CLL cells varied in their 
capacity to respond to IgM ligation (Hivroz et al. 1986, Karray et al. 1987). In general, CLL 
cells were less able to respond to BCR stimulation than normal B cells (Lankester et al. 1995). 
Furtermore, several investigators found that, upon IgM crosslinking, CLL cells with 
unmutated Ig genes showed significantly increased levels of tyrosine-phosphorylated 
proteins, including Syk, compared to CLL cells that expressed mutated Ig receptors 
(Lanham et al. 2003, Chen et al. 2002). Remarkably, this was not related to differences in the 
levels of Syk protein found (Semichon et al. 1997).  
In 2002, Chen et al. linked this phenomenon to the expression of ZAP-70. They found a 
greater increase in Syk tyrosine phosphorylation in cells expressing ZAP-70 compared to 
CLL cells lacking the protein. Consistent with this notion, they found that, besides Syk, also 
ZAP-70 itself undergoes tyrosine phosphorylation and complexes with the proteins of the 
BCR complex. At that time, two possible explanations were put forward. ZAP-70 might 
function to enhance BCR signaling by phosphorylation of specific motifs in CLL cells and 
thereby lower the threshold for Syk phosphorylation. Alternatively, expression of ZAP-70 in 
CLL cells might enhance the stability of phosphorylated Syk, allowing accumulation of the 
functional form of Syk in CLL cells.  
In a subsequent study, the same group (Chen et al. 2005) examined samples that expressed 
unmutated IgVH genes without ZAP-70 or samples carrying mutated IgVH genes with ZAP-
70, allowing them to examine the relative importance of ZAP-70 versus the IgVH mutational 
status in influencing the relative intensity of IgM signaling. A greater Ca2+ influx was seen in 
samples expressing ZAP-70 independently of the mutational status. Therefore, it was 
concluded that the induced increase in phosphorylated forms of Syk, BLNK or PLCǄ and 
Ca2+ influx after IgM ligation appeared more closely associated with the expression of ZAP-
70, rather than with the expression of unmutated IgVH. However, it could not be excluded 
that secondary factors other than ZAP-70 might also have been associated with the 
mutational status of the leukemic cells. To challenge this hypothesis it was required to 
transduce the CLL cells. Transduction studies revealed that expression of ZAP-70 in initially 
ZAP-70-negative CLL cells was sufficient to enhance IgM signaling. 
4.2.3 ZAP-70 tyrosine phosphorylation 
Gobessi et al. explored in 2007 the phosphorylation of ZAP-70 in CLL cells (Gobessi et al. 
2007). ZAP-70 was found to be inefficiently activated in CLL and relatively weakly activated 
compared to Syk. Phosphorylation of Tyr319 and Tyr493 could not be detected. 
Phosphorylation of these tyrosines are required for the catalytic activation of ZAP-70 (Figure 
1). Phosphorylation of the corresponding tyrosines in Syk was readily detectable with the 
same phospho-specific antibodies (Gobessi et al. 2007). ZAP-70 contains additional sites of 
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tyrosine phosphorylation (Figure 1) not involved in the regulation of its catalytic activity, 
but regulating the recruitment of downstream signaling molecules and adaptor proteins. 
With the use of specific antibodies against Tyr292 constitutive phosphorylation of Tyr292 in 
CLL B cells was demonstrated. Although, BCR stimulation did not induce a significant 
change in the level of Tyr292 phosphorylation, suggesting that the interactions mediated by 
this tyrosine do not require additional phosphorylation. Instead, after IgM ligation an 
association between c-Cbl and PI3K and ZAP-70 (Gobessi et al. 2007) was observed. 
Additionally, an association between ZAP-70 and Shc, which requires phosphorylation at 
Tyr474, was detected. The same authors, in agreement with Chen et al. (2005), reported a 
stronger and prolonged BCR-induced phosphorylation of Syk, ERK and Akt in ZAP-70 
transfected CLL cells. 
4.2.4 Molecular interactions of ZAP-70 in CLL and downstream effects 
To our knowledge, how ZAP-70 enhances BCR signaling in CLL cells is not known. It is 
conceivable that the capacity of ZAP-70 to enhance BCR signaling is not dependent upon its 
kinase activity. Two findings support this hypothesis. First, although Syk and ZAP-70 play 
similar roles in receptor signaling, Syk has approximately a 100-fold greater kinase activity 
in vitro than does ZAP-70 (Latour et al. 1996). Second, the kinase specific tyrosines are not 
phosphorylated in CLL cells (Gobessi et al. 2007). To address this, Chen et al. (Chen et al. 
2007) transduced ZAP-70 negative cells with an adenovirus containing a ZAP-70 lacking 
kinase activity. In these cells, similar responses were observed after IgM stimulation 
compared to CLL cells naturally expressing ZAP-70 or cells being transduced with the wild-
type ZAP-70. This unequivocally shows that ZAP-70 doesn’t enhance BCR signaling by 
means of its intrinsic kinase activity.  
Subsequently, Chen et al. as well as Gobessi et al. considered the hypothesis that ZAP-70 
instead may enhance BCR signaling indirectly by enhancing the stability of activated Syk 
following ligation of the BCR. It is known that activated ZAP-70 and Syk are targets of 
the E3 ubiquitin ligase, c-Cbl, which in turn directs polyubiquitination and proteosomal 
degradation of the activated PTK (Fournel et al. 1996, Lupher et al. 1998, Rao et al. 2002). 
Possibly, the activated ZAP-70 may compete with activated Syk for binding to c-Cbl and 
thereby prolong the half-life of activated Syk. However, transduction of CLL cells with 
an adenovirus encoding a mutant form of ZAP-70 carrying a mutation at position 292, 
which abrogates the ability of the mutant form to interact with c-Cbl, also enhanced BCR 
signaling of ZAP-70 negative CLL cells. So, binding of C-cbl to Tyr292 (Gobessi et al. 
2007) is unlikely to account for the capacity of ZAP-70 to enhance BCR signaling in CLL 
B cells.  
Another explanation, proposed by both groups, is that ZAP-70 functions as an adaptor 
protein that facilitates the recruitment of other signaling molecules to the activated BCR. The 
associations with PI3K and Shc after IgM stimulation are noteworthy in this respect because 
these proteins are involved in the activation of Akt and ERK, respectively (Gobessi et al. 
2007). In addition to this, examination of additional constructs encoding mutant forms of 
ZAP-70 that lacked a functional SH2 domain revealed that both SH2 domains are required 
for enhanced IgM signaling. This suggests that docking at the ITAM may be necessary for 
ZAP-70 to have an effect on CLL Ig receptor signaling (Chen et al. 2007).  
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The finding that ZAP-70 may enhance IgM signaling by functioning as an adaptor protein is 
further confirmed by zum Buschenfelde et al. (2010). The interaction of Ig receptors with 
their ligands has been shown to occur within an organized contact zone known as the 
immune synapse. Formation of the immune synapse is accompanied by a remodeling of 
specialized membrane microdomains enriched in sphingolipids and cholesterol known as 
lipid rafts (Viola & Gupta 2007). In T cells, ZAP-70 is known to be required for clustering 
signaling molecules into lipid rafts (Blanchard et al. 2002). This group investigated the 
distribution of ZAP-70 and signaling molecules like PKC-ǃII in lipid raft domains before 
and after BCR stimulation . They found that ZAP-70 was constitutively expressed in the raft 
domains. Accordingly, these cells constitutively expressed PKC-ǃII in lipid rafts, whereas 
the expression of PKC-ǃII was negligible in raft fractions of ZAP-70 negative patients, 
although total amounts of PKC-ǃII was expressed in the same amounts in whole-cell lysates 
in both groups. Signaling through the BCR recruited accessory ZAP-70 and PKC-ǃII into 
lipid raft domains (zum Buschenfelde et al. 2010). These experiments demonstrate that ZAP-
70 may function as an adaptor protein in specific lipid raft domains, and therefore recruits 
specific signaling molecules towards the immune synapse. 
Although reduced BCR internalization by ZAP-70 is never established in CLL cells, it could 
be a fourth explanation for increasing the magnitude and duration of BCR signaling. 
Transfection of ZAP-70 in BJAB B cells downmodulates BCR internalization (Gobessi et al. 
2007) explaining how ZAP-70 could contribute to the stronger signaling observed in CLL B 
cells.  
As described above, an important mediator of BCR signaling is NFκB, encoded by a 
family of transcription factors which are key regulators of differentiation and survival in 
B cells. In humans they include five members: c-Rel, Rel B, p50, p52 and p65 or Rel A. 
These factors form homo- or heterodimers, which in the resting state are retained in the 
cytoplasm by binding to the inhibitory IκB proteins. Upon different stimuli, including 
ligation of BCR, the IκB proteins are phosphorylated by IκB kinases (IKK) and degraded 
by the proteasome. Consequently, the NFκB dimers become free to translocate to the 
nucleus and activate the transcription of their target genes. These include antiapoptotic 
genes (Bcl-2, Mcl-1, Survivin), inflammatory genes (COX-2, MMP-9, VEGF) and genes 
encoding adhesion molecules, chemokines (IL-1ǃ, IL-6, IL-8) and cell cycle regulatory 
proteins (Cyclin D1, c-Myc) (Hayden & Ghosh 2008). More generally, NFκB has been 
implicated in tumorigenesis and survival of a growing list of leukemias and lymphomas 
(Karin & Lin 2002).  
CLL cells have been reported to exhibit high constitutive NFκB activation compared with 
normal B lymphocytes (Cuni et al. 2004, Furman et al. 2000, Tracey et al. 2005). Although the 
exact factors responsible for the constitutive expression of NFκB are not fully resolved, 
many factors, including Akt activation, BCR signaling, CD40 ligation, IL-4 and B cell 
activating factor (BAFF), have been shown to increase NFκB activity and enhance CLL 
survival, with members of the Bcl-2 family being principal transcriptional targets 
(Petlickovski et al. 2005). Hewamana (2008) found an association between ZAP-70 
expression and the ability of CLL cells to activate NFκB (Hewamana et al. 2008). 
Furthermore, they found that the magnitude of the change in NFκB after stimulation with 
anti-IgM is associated with the suppression of in vitro apoptosis. Lopez-Guerra et al. (2009) 
tested a specific IκB kinase inhibitor, BMS-435541, and found that CLL cells expressing ZAP-
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70 are more sensitive to this IKK inhibitor compared to CLL cells without ZAP-70. This 
supports the hypothesis that there is a functional link between ZAP-70 and NFκB. On the 
other hand, these results also imply that the therapeutic combination of NFκB inhibitors 
with other chemotherapeutic drugs, represents a novel strategy especially for the group 
with high ZAP-70, known to be more resistant to agents currently in use (Lopez-Guerra et 
al. 2009).  
 
Schematic presentation of the interaction of ZAP-70 into the intracellular signaling pathways occurring in a CLL 
cell after stimulation of the B cell receptor. Syk, BLNK, PLCγ, MAPK, PKC and NFκB (enclosed by a red line) are 
potentially stimulated by ZAP-70. Also the phosphorylation of Syk (red P) and calcium influx (red arrow) may be 
augmented by ZAP-70. 
Fig. 4. ZAP-70 in CLL signaling in poor prognosis CLL 
5. Interaction of ZAP-70 with the leukemic microenvironment 
In contrast with their long-living capacities in the human body, CLL cells tend to undergo 
rapid apoptotic cell death when incubated in vitro. This has raised the hypothesis of pro-
survival environmental factors existing in vivo, supporting the CLL cells in their survival 
and growth (Ghia et al. 2002).  
The peripheral blood of CLL patients contains an accumulation of mature B cells that have 
escaped programmed cell death and have undergone cell cycle arrest in the G0/G1 phase 
lacking metabolic activity. However, when in in vivo experiments patients drank deuterated 
water (2H2O) cell generation rates were in the range between 0,1 to 1,75 % of the entire CLL 
clone per day (Messmer et al. 2005). Considering a CLL clone to contain 1012-1014 cells, an 
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extensive number of 109 to 1012 cells are produced each day. This implies that, although there is 
a virtual absence of proliferative cells in peripheral blood, ill-defined areas of proliferation are 
existing in the bone marrow and affected lymph nodes (Herishanu et al. 2011). Indeed, 
interactions with stromal cells, or nurse-like cells, or interactions between CD38 and its ligand 
CD31 rescue CLL cells from apoptosis in vitro and probably do the same in vivo (Chiorazzi et 
al. 2005), and furthermore enhance proliferation of the cells. Below, several interactions 
between CLL cells and by-stander cells will be discussed, especially those findings that 
correlate with the more aggressive nature of the ZAP-70 positive disease. 
5.1 CD38 and ZAP-70 
CD38 is a transmembrane glycoprotein that mediates cell-cell interactions (Deaglio et al. 
1998). CD38 expression is significantly associated with unmutated IgVH genes in CLL, also 
with ZAP-70 and subsequently with a more aggressive disease (Damle et al. 1999).  
In CLL, chemokines are reported to contribute significantly to the delivery of growth signals 
to the malignant CLL cells expressing functional receptors. Knowing that ZAP-70 is an 
essential element in the signaling cascade initiated via CXCR4 in T cells and knowing that 
the combination of CD38 and ZAP-70 defines a subgroup of patients with the highest 
migratory potential towards the ligand for CXCR4, SDF1ǂ, it is tempting to speculate that 
the CD38-ZAP-70 axis synergizes with the SDF1ǂ-CXCR4 pathway (Deaglio et al. 2007).  
SDF1ǂ has previously been shown to exert both a chemotactic effect and a prosurvival effect 
on CLL cells, being a crucial mechanism through which stromal cells or nurse like cells 
support CLL cells in vitro (Burger et al. 1999, Burger et al. 2000). The finding that CLL cells 
proliferate at sites where stromal cells are present suggest that SDF1ǂ is an important factor 
in CLL pathogenesis. Moreover, several groups confirmed an increased level of CXCR4 on 
the surface of CLL cells when compared with normal B cells (Richardson et al. 2006, Mohle 
et al. 1999, Burger et al. 1999). Treatment of CLL cells with SDF1ǂ resulted in a rapid and 
sustained ERK activation profile only in the ZAP-70 positive subgroup. Furthermore, 
treatment with SDF1ǂ in vitro of ZAP-70 positive but not in ZAP-70 negative cells, resulted 
in a longer survival. Sustained ERK activation can lead to the initiation of transcription of 
genes involved in both proliferation and survival (Burger et al. 2000, Xia et al. 1995, Murphy 
et al. 2002). This could be the explanation for both survival and proliferative advantages 
seen in ZAP-70 positive cells. These results indicate that ZAP-70 positive cells are more 
responsive to signals derived from their surrounding environment.  
5.2 CCR7 and ZAP-70 
Several groups found that CCR7 is upregulated on the surface of circulating peripheral 
blood CLL cells when compared with healthy control peripheral blood B cells (Richardson 
et al. 2006, Till et al. 2002, Lopez-Giral et al. 2004, Ghobrial et al. 2004). Moreover, 
Richardson et al. (2006) demonstrates that CCR7 levels are increased in ZAP-70 positive CLL 
cells when compared with ZAP-70 negative CLL cells. This upregulation in CCR7 confers an 
increased ability to respond to its ligands, CCL19 and CCL21. Both chemokines are 
important in both T and B lymphocyte trafficking (Figure 5). Prior studies in B cells (Reif et 
al. 2002) have shown that antigen engagement upregulates expression of CCR7 and can 
facilitate the movement of these cells into the lymph nodes and localization to the B/T cells 
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LN: lymph nodes; HEV: high endothelial venules 
Upper: CLL ZAP- cells;  
Lower: CLL ZAP+ cells: In ZAP-70 positive cells, increased levels of CCR7 and the interplay between ZAP-70, 
CD38 and CXCR4 facilitate movement and migratory potential towards lymph nodes. 
Fig. 5. Migration of CLL cells towards the lymph nodes 
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boundary. Since increased CCR7 expression has been documented following antigen 
contact, this could be reflecting either an increased level of antigen contact, which is likely to 
be the case for both ZAP-70 positive and ZAP-70 negative CLL B cells, as both cell types 
have been shown to resemble activated B cells (Damle et al. 2002, Herishanu et al. 2011), or 
an increased ability to respond to antigen contact. Herishanu et al. (2011) further described 
the increased proliferative signature of the CLL cells residing in the lymph nodes and bone 
marrow, due to a more intensive BCR triggering. ZAP-70 helps in a more sustained 
activation state after BCR triggering. The finding that CCR7 levels are lower in lymph node 
CLL cells than in peripheral blood CLL cells is suggestive of it being involved in migration 
to the lymph nodes (Till et al. 2002, Lopez-Giral et al. 2004, Ghobrial et al. 2004).  
6. Summary 
It remains largely unkown why ZAP-70 is or is not expressed in CLL. Hsp90 may be 
important in this respect. Although the precise molecular mechanism of the role of ZAP-70 
in CLL B cells is not yet fully resolved, many hypotheses have been put forward suggesting 
multiple functions. Strikingly, it is improbable that ZAP-70 exerts its role by its kinase 
activity. ZAP-70 in CLL may be stabilizing SYK, creating more sustained phosphorylation 
and in association increasing the proliferative capacity. Moreover, ZAP-70 functions as an 
adaptor protein that facilitates the recruitment of other signaling molecules to the activated 
BCR. Also the internalization of the BCR after stimulation may be reduced due to 
intervention of ZAP-70. An important mechanism explaining prolonged survival of CLL 
cells has been attributed to its interaction with the microenvironment. In this interaction, 
ZAP-70 may also be of relevance. 
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